{"id":2495,"date":"2018-10-24T13:05:40","date_gmt":"2018-10-24T13:05:40","guid":{"rendered":"https:\/\/www.mybiosource.com\/learn\/?p=2495"},"modified":"2023-03-13T12:42:21","modified_gmt":"2023-03-13T12:42:21","slug":"influenza-series-recommendations-and-actions-initiated-by-cdc-for-influenza","status":"publish","type":"post","link":"https:\/\/www.mybiosource.com\/learn\/influenza-series-recommendations-and-actions-initiated-by-cdc-for-influenza\/","title":{"rendered":"Influenza Series: Recommendations and Actions Initiated by CDC for Influenza"},"content":{"rendered":"\n\n\n
\n

Table of Contents<\/u><\/strong><\/h3>\n

I. Introduction<\/strong><\/a>
\n\u2022 Identification of active virus as influenza A(H1N1)pdm09
\n\u2022 Overview of influenza as a global illness and cause of death
\nII. Antiviral Treatment Recommendations<\/strong><\/a>
\n\u2022 Five licensed prescription antiviral drugs in the US
\n\u2022 Neuraminidase inhibitors as treatment options for influenza season 2017-2018
\nIII. Treatment Duration or Chemoprophylaxis Treatment<\/strong><\/a>
\n\u2022 Recommended duration for oral oseltamivir and inhaled zanamivir
\n\u2022 Single dose of intravenous peramivir for uncomplicated influenza
\n\u2022 Oral oseltamivir preferred for pregnant women or women up to two weeks postpartum
\nIV. Influenza Vaccines Recommendations for 2018-2019<\/strong><\/a>
\n\u2022 Review and update of vaccine composition to effectively target circulating viruses
\n\u2022 Shots made with adjuvant
\n\u2022 Shots made with virus grown in cell culture
\n\u2022 Live attenuated influenza vaccine (LAIV)
\nV. Conclusion<\/strong><\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The weekly U.S Influenza<\/span> surveillance report published in the Centers for Disease Control and Prevention<\/span> shows the influenza<\/span> activity has continued to remain low in the country for the current influenza<\/span> season. However, the active virus circulating is identified as influenza<\/span> A(H1N1<\/span>)pdm09 reported in the recent three weeks. In the United States, Guam and two States shows local influenza<\/span> activity, forty states with sporadic activity and one influenza<\/span>-related pediatric death has so far been reported. According to the WHO, the second most common illness globally is influenza<\/span> and is the third cause of death. And hence, CDC recommends appropriate measures that need to be taken to prevent the infection and to effectively treat it with antivirals to stop the complications that can develop particularly among the high risk group of people. Here we discuss the actions and recommendations by CDC for the initiation of antiviral<\/span> treatment, its duration or chemoprophylaxis and vaccine recommendations for the season 2017-2018.<\/p>\n

 <\/p>\n

Antiviral Treatment Recommendations For the treatment of influenza<\/span>, there are five licensed prescription antiviral<\/span> drugs in the United States. The three antiviral<\/span> drugs approved by the FDA are known as neuraminidase<\/span> inhibitors and are available as treatment options for the influenza<\/span> season 2017-2018. The neuraminidase<\/span> inhibitors are oral oseltamivir<\/span>, inhaled zanamivir<\/span> and intravenous peramivir<\/span>. Antiviral<\/span> drugs belonging to the class of medications called adamantanes are amantadine<\/span> and rimatadine which are only active against influenza<\/span> A. Due to the high levels of resistance, adamantanes are not recommended for the treatment of influenza<\/span>. According to the CDC, the antiviral<\/span> treatment should be initiated;<\/p>\n